Latest Period
Q1 2026
Security Snapshot
Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) Institutional Ownership
CUSIP: 68622P109
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
181
Shares (Excl. Options)
119,357,939
Price
$12.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- ORIC on Nasdaq
- Shares outstanding
- 105,956,500
- Price per share
- $10.19
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 119,357,939
- Total reported value
- $1,509,861,161
- % of total 13F portfolios
- 0.01%
- Share change
- -679,483
- Value change
- +$11,114,140
- Number of holders
- 181
- Price from insider filings
- $10.19
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ORIC - Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 68622P109.
- 181 institutions reported positions in Q1 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 165 to 181 between Q4 2025 and Q1 2026.
- Reported value moved from $979,579,552 to $1,509,861,161.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 181 institutions filings for Q1 2026.
Security key
68622P109
Latest holder period
Q1 2026
13F holders
181
13D/G owners
12
CIK / CUSIP context first
Open Q1 2026 holders
ORIC full holder history
Oric Pharmaceuticals, Inc. SEC filings
Oric Pharmaceuticals, Inc. company facts
Oric Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68622P109:
Significant Owners of Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 7.8% | -22% | $85,951,913 | -$4,833,275 | 8,264,607 | -5.3% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 |
| Nextech Crossover I GP S.a r.l. | 8.4% | $78,072,743 | 7,162,637 | Nextech Crossover I GP S.a. r.l. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 6.9% | $73,336,464 | 6,728,116 | EcoR1 Capital, LLC | 29 Jul 2025 | |||
| BlackRock, Inc. | 5.6% | +35% | $44,773,610 | +$15,158,006 | 5,473,145 | +51% | BlackRock, Inc. | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.4% | $56,032,943 | 5,387,783 | T. Rowe Price Associates, Inc. | 31 Mar 2026 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | 4.8% | -13% | $50,307,686 | 4,615,384 | 0% | SR One Capital Management, LLC | 12 Aug 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC | 4.6% | $54,049,152 | 4,504,096 | Alkeon Capital Management LLC | 30 Sep 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | -27% | $44,925,556 | -$14,107,236 | 4,319,765 | -24% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| COLUMN GROUP II, LP | 3.7% | $48,612,534 | 3,644,118 | Peter Svennilson | 30 Sep 2025 | |||
| PFIZER INC | 3.3% | $35,806,576 | 3,442,940 | Pfizer Inc. (IRS Identification No.: 13-5315170) | 31 Mar 2026 | |||
| FMR LLC | 3.5% | $13,967,797 | 2,467,809 | FMR LLC | 31 Dec 2024 | |||
| Frazier Life Sciences Public Fund, L.P. | 2% | $7,981,692 | 1,410,193 | James N. Topper | 31 Mar 2025 |
As of 31 Mar 2026, 181 institutional investors reported holding 119,357,939 shares of Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC). This represents 113% of the company’s total 105,956,500 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 6.8% | 7,162,637 | 0% | 6.4% | $90,750,611 |
| EcoR1 Capital, LLC | 6.3% | 6,728,116 | 0% | 3.6% | $85,245,230 |
| BlackRock, Inc. | 5.6% | 5,984,552 | +1.9% | 0% | $75,824,274 |
| VIKING GLOBAL INVESTORS LP | 5.5% | 5,824,533 | -11% | 0.21% | $73,796,833 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.1% | 5,387,783 | +64% | 0.01% | $68,264,000 |
| Pfizer Inc | 4.5% | 4,780,401 | -11% | 24% | $57,651,636 |
| SR One Capital Management, LP | 4.3% | 4,514,929 | 0% | 6.4% | $58,476,915 |
| ALKEON CAPITAL MANAGEMENT LLC | 4.3% | 4,504,096 | 0% | 0.26% | $57,066,896 |
| Venrock Adviser, LLC | 4.1% | 4,319,765 | -24% | 2% | $54,731,423 |
| NEA Management Company, LLC | 3.9% | 4,118,621 | 0% | 3% | $52,182,928 |
| STATE STREET CORP | 3.5% | 3,702,196 | -13% | 0% | $46,906,823 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 3,687,007 | 0% | 0% | $46,714,379 |
| Column Group LLC | 3.3% | 3,540,777 | 0% | 45% | $44,861,645 |
| Siren, L.L.C. | 2.8% | 2,998,192 | +198% | 1.1% | $37,987,092 |
| ORBIMED ADVISORS LLC | 2.5% | 2,693,929 | -26% | 0.77% | $34,132,080 |
| AIHC Capital Management Ltd | 2.3% | 2,459,551 | 26% | $31,162,511 | |
| FMR LLC | 2.3% | 2,434,080 | -1.8% | 0% | $30,839,793 |
| CITADEL ADVISORS LLC | 2.3% | 2,422,741 | -0.49% | 0.02% | $30,696,128 |
| First Turn Management, LLC | 1.9% | 2,017,284 | +0.35% | 2.9% | $25,558,988 |
| Vivo Capital, LLC | 1.7% | 1,848,786 | -13% | 1.9% | $23,424,119 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,838,801 | +5% | 0% | $23,302,207 |
| MPM BIOIMPACT LLC | 1.7% | 1,803,945 | +0.29% | 1.8% | $22,855,983 |
| Paradigm Biocapital Advisors LP | 1.6% | 1,701,217 | -29% | 0.44% | $21,554,419 |
| MORGAN STANLEY | 1.6% | 1,682,523 | +41% | 0% | $21,317,567 |
| GOLDMAN SACHS GROUP INC | 1.4% | 1,475,712 | -24% | 0% | $18,697,271 |
Institutional Holders of Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 119,357,939 | $1,509,861,161 | +$11,114,140 | $12.67 | 181 |
| 2025 Q4 | 119,653,820 | $979,579,552 | +$96,243,084 | $8.18 | 165 |
| 2025 Q3 | 106,492,104 | $1,277,897,818 | +$159,574,138 | $12.00 | 151 |
| 2025 Q2 | 93,349,298 | $947,499,065 | +$169,716,912 | $10.15 | 140 |
| 2025 Q1 | 79,209,337 | $442,004,992 | +$11,923,513 | $5.58 | 142 |
| 2024 Q4 | 75,794,185 | $611,682,254 | -$16,308,147 | $8.07 | 129 |
| 2024 Q3 | 69,823,199 | $715,076,569 | +$22,655,622 | $10.25 | 121 |
| 2024 Q2 | 67,575,796 | $477,762,911 | +$20,174,043 | $7.07 | 111 |
| 2024 Q1 | 63,945,767 | $879,254,046 | +$197,777,720 | $13.75 | 110 |
| 2023 Q4 | 50,638,764 | $465,880,631 | +$34,655,080 | $9.20 | 91 |
| 2023 Q3 | 48,053,106 | $290,723,321 | +$14,148,790 | $6.05 | 89 |
| 2023 Q2 | 45,537,877 | $353,374,535 | +$99,111,683 | $7.76 | 83 |
| 2023 Q1 | 33,075,099 | $188,527,951 | +$3,515,469 | $5.70 | 70 |
| 2022 Q4 | 32,430,291 | $192,141,081 | +$135,543 | $5.89 | 64 |
| 2022 Q3 | 32,701,288 | $104,643,704 | -$1,866,676 | $3.20 | 69 |
| 2022 Q2 | 32,837,327 | $147,127,000 | -$6,223,365 | $4.48 | 77 |
| 2022 Q1 | 33,856,070 | $180,750,917 | -$7,186,800 | $5.34 | 94 |
| 2021 Q4 | 34,857,324 | $512,119,938 | -$36,775,082 | $14.70 | 79 |
| 2021 Q3 | 31,534,174 | $659,370,855 | +$8,490,366 | $20.91 | 78 |
| 2021 Q2 | 36,145,561 | $639,409,737 | +$2,954,162 | $17.69 | 78 |
| 2021 Q1 | 35,685,685 | $874,284,848 | +$71,774,159 | $24.50 | 82 |
| 2020 Q4 | 32,607,853 | $1,103,814,951 | +$273,075,064 | $33.85 | 76 |
| 2020 Q3 | 22,151,969 | $552,859,000 | +$7,647,968 | $25.01 | 53 |
| 2020 Q2 | 21,388,813 | $718,339,063 | +$718,339,063 | $33.73 | 64 |